Xencor announces ESMO 2026 oral presentation for Phase 1 XmAb819 kidney cancer study
The company said data from its Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma was selected for a proffered paper oral presentation at ESMO 2026.